Crossmark

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1136/jitc-2021-004291

Published Online: 2022-03-25

Published Print: 2022-03

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Liu, Jun

Yang, Yang

Liu, Zhichao https://orcid.org/0000-0003-3542-0905
Fu, Xiaolong

Cai, Xiaoyue

Li, Hongxuan

Zhu, Li

Shen, Yan

Zhang, Hong

Sun, Yifeng

Chen, Hezhong

Yu, Bentong

Zhang, Renquan

Shao, Jinchen

Zhang, Ming

Li, Zhigang https://orcid.org/0000-0001-5086-5334
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05043688 at ClinicalTrials.gov

Documents that mention this clinical trial

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
https://doi.org/10.1136/jitc-2021-004291
Funding

Funding for this research was provided by:

Jiangsu Hengrui Pharmaceutical Co., Ltd

National Natural Science Foundation of China (82172756)
License Information

License valid from 2022-03-24

Document is current

Any future updates will be listed below